Shenzhen:300363

Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors

Retrieved on: 
Monday, March 13, 2023
Proton, Neoplasm, Plasmid, Cell, Gene, CDMO, TIL, Messenger, Partnership, Pharmaceutical industry, Vaccine

SUZHOU, China, March 13, 2023 /PRNewswire/ -- On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. (Porton Advanced) and Bennu Biotherapeutics (Bennubio) announced a strategic partnership to advance cell and gene therapy R&D pipelines.

Key Points: 
  • SUZHOU, China, March 13, 2023 /PRNewswire/ -- On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. (Porton Advanced) and Bennu Biotherapeutics (Bennubio) announced a strategic partnership to advance cell and gene therapy R&D pipelines.
  • As an end-to-end gene and cell therapy service CDMO, Porton Advanced provides comprehensive solutions covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy.
  • Under this strategic agreement, Porton Advanced will provide CDMO services for multiple pipelines for gene and cell therapy, including plasmids, virus, TIL, TCR-T, and Treg, to Bennu Biotherapeutics.
  • Ms. Zhao Ping, Co-founder and CEO of Bennu Biotherapeutics, said, "We can advance our process development and production by utilizing the advanced process development technologies provided by Porton Advanced.

Porton Advanced and Yinjia Biosciences Partner to Enhance CDMO Technology Platform

Retrieved on: 
Friday, February 24, 2023
Messenger, Plasmid, Partnership, Quality control, CGT, Therapy, Patient, Vaccine

Porton Advanced CDMO offers end-to-end gene and cell therapy services covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy.

Key Points: 
  • Porton Advanced CDMO offers end-to-end gene and cell therapy services covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy.
  • Yinjia Biosciences focuses on high-quality core protein raw materials and also offers companion diagnostics products for innovative adjuvant therapies.
  • Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
  • Porton Advanced will continue to advance its technology and capabilities to accelerate the development of CGT to meet clinical needs and empower global partners.

Porton Advanced Solutions completes a Series B financing round to expand its end-to-end Gene and Cell Therapy CDMO Platforms

Retrieved on: 
Monday, August 22, 2022
Momentum, Science and technology in Asia, CEO, Technology, Program, Research, Agriculture, View, Suzhou Industrial Park, Virus, TMT, LTD, Health, Science, CDMO, GMP, Medicine, Compliance, Plasmid, IP, AD, China Merchants Group, RNA transfection, CSC, Patient, Information, Parallel (filling stations operator), CMC, CGMP, GCT, Industry, AAV, Mining, Trust, Investment, EQUITY, AUM, IIT, Multimedia, API, Growth, Drug development, Empowerment, Transport, IND, HM Capital Partners, RMB, PD, Therapy, Record, Bank, Fine chemical, Pharmaceutical industry, Financial services, EU, Fosun International

SUZHOU, China, Aug. 21, 2022 /PRNewswire/ -- On August 19, 2022, Porton Advanced Solutions (Porton Advanced) announced the completion of its Series B financing round with over US$80Million.

Key Points: 
  • SUZHOU, China, Aug. 21, 2022 /PRNewswire/ -- On August 19, 2022, Porton Advanced Solutions (Porton Advanced) announced the completion of its Series B financing round with over US$80Million.
  • Focusing solely on gene and cell therapy CDMO services, Porton Advanced has rapidly established an integrated CDMO platform providing a spectrum of services covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vectors used for gene therapy (MVGTs).
  • By then, Porton Advanced will have over 200,000sqft of PD, AD, and GMP manufacturing facility dedicated for gene and cell therapy.
  • Porton Advanced is a leading cell and gene therapy CDMO service provider with a very experienced, internationally oriented management and technical team.